Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1293053 | 0.79 | TDP1 (0.52) | TDP1HTTFGFR1LMNASMN1; SMN2 | |
| SCHEMBL491202 | 0.76 | HTT (0.50) | TDP1HTTFGFR1LMNASMN1; SMN2 | |
| SCHEMBL3968932 | 0.76 | TDP1 (0.48) | TDP1HTTFGFR1LMNASMN1; SMN2 | |
| SCHEMBL6392854 | 0.76 | EGLN3 (0.46) | TDP1HTTFGFR1SMN1; SMN2HSD17B10 | |
| SCHEMBL8901472 | 0.76 | EGLN3 (0.46) | TDP1HTTFGFR1SMN1; SMN2HSD17B10 | |
| SCHEMBL8003415 | 0.76 | TDP1 (0.44) | TDP1HTTFGFR1LMNASMN1; SMN2 | |
| SCHEMBL3643581 | 0.75 | EGLN3 (0.43) | TDP1HTTFGFR1SMN1; SMN2HSD17B10 | |
| SCHEMBL4180919 | 0.74 | TDP1 (0.47) | TDP1HTTFGFR1LMNASMN1; SMN2 | |
| SCHEMBL9378132 | 0.74 | EGLN3 (0.49) | TDP1HTTFGFR1LMNASMN1; SMN2 | |
| SCHEMBL7068657 | 0.74 | FDPS (0.43) | TDP1HTTFGFR1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115532235-A | Lanthanum-based adsorbent and preparation method and application thereof | 湖南大学 | 2022-12-30 | — | — | CN | claimed |
| CN-113372787-B | Flame-retardant powder coating and preparation method thereof | 廊坊市亚龙三惠科技有限公司 | 2022-10-14 | — | — | CN | claimed |
| CN-113372787-A | Flame-retardant powder coating and preparation method thereof | 廊坊市亚龙三惠科技股份有限公司 | 2021-09-10 | — | — | CN | claimed |
| CN-111718324-A | Composition based on benzimidazole carboxylic acid compounds and application thereof | 嘉兴市爵拓科技有限公司 | 2020-09-29 | — | — | CN | claimed |
| CN-110016016-A | Benzimidazole carboxylic acid fragment and preparation method thereof in a kind of GSK484 | 绍兴文理学院 | 2019-07-16 | — | — | CN | claimed |
| CN-103240060-A | Metal organogel as well as preparation and application thereof in treatment of dyeing wastewater | UNIV NORTHWEST NORMAL | 2013-08-14 | — | — | CN | claimed |
| EP-1831206-B1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARM INC (US) | 2011-08-24 | — | — | EP | claimed |
| JP-2008521903-A | — | — | 2008-06-26 | — | — | JP | claimed |
| EP-1831206-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006060381-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. | 2006-06-01 | — | — | US | claimed |
| JP-2000515506-A | — | — | 2000-11-21 | — | — | JP | claimed |
| EP-0920312-A4 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2000-11-02 | — | — | EP | claimed |
| EP-0920312-A1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | Galderma Research & Development (FR) | 1999-06-09 | — | — | EP | claimed |
| WO-1998001132-A1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-01-15 | — | — | WO | claimed |
| US-4814400-A | Polybenzimidazole ester and carboxylic acid | HOECHST CELANESE CORPORATION (US) | 1989-03-21 | — | — | US | claimed |
| JP-2174775-A | — | — | None | — | — | JP | disclosed |
| JP-7165580-A | — | — | None | — | — | JP | disclosed |
| US-3958007-A | FUNGICIDES, MITE OVICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-05-18 | — | — | US | disclosed |
| US-3950391-A | FUNGICIDES, MITICIDES, OVICIDES | ADAMS CHARLES D | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | KIT, CHUK, TNNI3K | TDP1 4069/4885HTT 4644/4885FGFR1 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.